Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
03 Dec 2015 FDA Approves Elotuzumab for the Treatment of Multiple Myeloma Haematologic malignancies - Anticancer agents & Biologic therapy
02 Dec 2015 Lung Adenocarcinoma With HER2 Mutations Personalised medicine - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
01 Dec 2015 NHS England and NICE Have Begun a Consultation on a New Cancer Drugs Fund Bioethics, legal and economic issues
30 Nov 2015 FDA Approves Nivolumab as a Single Agent for Previously Untreated BRAF Wild-Type Advanced Melanoma Melanoma - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy
27 Nov 2015 FDA Approves Necitumumab to Treat Advanced Squamous NSCLC Lung and other thoracic tumours - Anticancer agents & Biologic therapy
26 Nov 2015 European Medicines Agency Recommends Granting a Marketing Authorisation for Pemetrexed Accord and Pemetrexed Actavis Lung and other thoracic tumours - Anticancer agents & Biologic therapy
25 Nov 2015 FDA Approves Ixazomib, New Oral Proteasome Inhibitor for Treatment of Multiple Myeloma Haematologic malignancies - Anticancer agents & Biologic therapy
24 Nov 2015 FDA Approves Nivolumab for the Treatment of Advanced Renal Cell Cancer Genitourinary cancers - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy
24 Nov 2015 European Medicines Agency Recommends Granting a Marketing Authorisation for Asparaginase and Pegaspargase Haematologic malignancies - Anticancer agents & Biologic therapy
19 Nov 2015 FDA Approves Daratumumab for Patients With Previously Treated Multiple Myeloma Haematologic malignancies
18 Nov 2015 Dabrafenib Produces Rapid Shrinkage of Recurrent, BRAF-mutant Papillary Craniopharyngioma Personalised medicine - Endocrine cancers - Anticancer agents & Biologic therapy
17 Nov 2015 Distinct Evolutionary Trajectories Reported for Different Melanoma Subtypes Pathology/Molecular biology - Melanoma
16 Nov 2015 FDA Approves Osimertinib to Treat Patients With EGFR T790M Positive Advanced NSCLC After Progression to Other EGFR Tyrosine Kinase Inhibitors Personalised medicine - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
12 Nov 2015 FDA Approves Cobimetinib as Part of Combination Treatment for Advanced Melanoma Melanoma - Anticancer agents & Biologic therapy
11 Nov 2015 Immunosurveillance in Breast Cancer Breast cancer - Cancer Immunology and Immunotherapy